- Home
- HIO vs ERAS Comparison
HIO vs ERAS Comparison
Compare HIO & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIO
- ERAS
- Stock Information
- Founded
- HIO 1993
- ERAS 2018
- Country
- HIO United States
- ERAS United States
- Employees
- HIO N/A
- ERAS N/A
- Industry
- HIO Finance/Investors Services
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- HIO Finance
- ERAS Health Care
- Exchange
- HIO Nasdaq
- ERAS Nasdaq
- Market Cap
- HIO 368.0M
- ERAS 439.7M
- IPO Year
- HIO N/A
- ERAS 2021
- Fundamental
- Price
- HIO $3.86
- ERAS $2.42
- Analyst Decision
- HIO
- ERAS Buy
- Analyst Count
- HIO 0
- ERAS 6
- Target Price
- HIO N/A
- ERAS $3.67
- AVG Volume (30 Days)
- HIO 305.3K
- ERAS 1.8M
- Earning Date
- HIO 01-01-0001
- ERAS 11-07-2025
- Dividend Yield
- HIO 10.33%
- ERAS N/A
- EPS Growth
- HIO N/A
- ERAS N/A
- EPS
- HIO N/A
- ERAS N/A
- Revenue
- HIO N/A
- ERAS N/A
- Revenue This Year
- HIO N/A
- ERAS N/A
- Revenue Next Year
- HIO N/A
- ERAS N/A
- P/E Ratio
- HIO N/A
- ERAS N/A
- Revenue Growth
- HIO N/A
- ERAS N/A
- 52 Week Low
- HIO $3.52
- ERAS $1.01
- 52 Week High
- HIO $4.03
- ERAS $3.31
- Technical
- Relative Strength Index (RSI)
- HIO 50.33
- ERAS 56.95
- Support Level
- HIO $3.81
- ERAS $2.34
- Resistance Level
- HIO $3.88
- ERAS $2.54
- Average True Range (ATR)
- HIO 0.04
- ERAS 0.15
- MACD
- HIO 0.01
- ERAS -0.02
- Stochastic Oscillator
- HIO 76.92
- ERAS 51.58
About HIO Western Asset High Income Opportunity Fund Inc.
Western Asset High Income Oppor Fd Inc is a diversified closed-end management investment company. The company's primary objective is to seek high current income and the secondary objective is capital appreciation. It invests a majority of its net assets in high-yield corporate debt securities and the rest in common stock equivalents, including options, warrants, and rights. The company invests in securities of companies from various sectors such as energy, technology, utilities, industrials, communications, finance, and capital goods among others.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.